WebLEXINGTON, Mass., March 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery ... Web31 dec. 2024 · Keros Therapeutics Stock (NASDAQ:KROS), Earnings Estimates, EPS, and Revenue Keros Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a...
Keros Therapeutics - KROS Stock Forecast, Price & News
WebKeros Therapeutics started at buy with $100 stock price target at Truist Oct. 18, 2024 at 7:23 a.m. ET by Tomi Kilgore Keros Therapeutics sets IPO terms, expects to raise up … Web13 apr. 2024 · Keros Therapeutics (NASDAQ:KROS) has a recorded net income of -$104.68 million. KROS has generated -$4.15 earnings per share over the last four … short film showcase
Keros Therapeutics - KROS - Stock Price Today - Zacks
WebTrading Signals for Keros Therapeutics Inc with Buy, Sell, Hold recommendations, technical analysis, and trading strategy. ... Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, ... WebKeros Therapeutics Powered by TGF-β science, inspired by patients At Keros, our mission is to innovate therapies that have the potential to shift the treatment paradigm for people living with hematological, pulmonary and cardiovascular disorders of high unmet medical … About - Keros Therapeutics Our Science - Keros Therapeutics Keros’ lead small molecule product candidate, KER-047, is being developed … Careers - Keros Therapeutics Contact Us - Keros Therapeutics Board of Directors - Keros Therapeutics Management - Keros Therapeutics Our Pipeline - Keros Therapeutics Web4 aug. 2024 · Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and musculoskeletal disorders with … sani beach holidays 2022